VILCHEMIE M 500 15'S

About

VILCHEMIE M 500 is a fixed-dose combination medication comprising Vildagliptin and Metformin, specifically formulated for the comprehensive management of type 2 diabetes mellitus. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, enhances the body's natural ability to control blood glucose by increasing the levels of active incretin hormones, which in turn boost insulin secretion and suppress glucagon release. Metformin, a biguanide, acts primarily by reducing hepatic glucose production, decreasing intestinal glucose absorption, and improving peripheral insulin sensitivity. This synergistic dual mechanism of action effectively targets multiple pathophysiological defects in type 2 diabetes, leading to significant reductions in both fasting and postprandial blood glucose levels. It is particularly beneficial for patients whose glycemic control is inadequate with metformin monotherapy or who require a more robust combination approach.

Uses

• Management of type 2 diabetes mellitus.
• Improvement of glycemic control in adults.
• Used as an adjunct to diet and exercise.
• When metformin monotherapy is insufficient.

Directions For Use

Take orally with meals to reduce gastrointestinal side effects, as prescribed by your doctor.

Benefits

• Improved glycemic control.
• Reduces both fasting and postprandial glucose.
• Low risk of hypoglycemia when used alone.
• Weight-neutral or modest weight loss.
• Enhances insulin sensitivity.
• Dual mechanism of action for comprehensive control.

Side Effects

• Nausea
• Diarrhea
• Abdominal pain
• Vomiting
• Headache
• Dizziness
• Nasopharyngitis
• Tremor
• Fatigue
• Lactic acidosis (rare, serious)
• Pancreatitis (rare)
• Vitamin B12 deficiency

Safety Measures

• Alcohol - Avoid excessive alcohol intake due to increased risk of lactic acidosis.
• Pregnancy - Not recommended; consult a doctor for alternative treatments.
• Breastfeeding - Not recommended; metformin passes into breast milk.
• Liver - Use with caution in mild to moderate impairment; contraindicated in severe liver disease.
• Kidney - Contraindicated in severe renal impairment (eGFR <30 mL/min/1.73m²) due to lactic acidosis risk.
• Lung - Use with caution in conditions causing hypoxia, as it may increase lactic acidosis risk.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.